Nifty
:
25044.35
Sensex
:
82055.11
72.45 (0.29%)
158.32 (0.19%)
Nifty
Sensex
:
:
25044.35
82055.11
72.45 (0.29%)
158.32 (0.19%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
66/99

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
964.55
24-Jun-2025
  • Open
  • High
  • Low
  • Previous Close
  •  962.1
  •  967.9
  •  955.85
  •  952.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1162909
  •  1119493678.55
  •  1324.3
  •  795

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 97,096.55
  • 21.46
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 97,309.25
  • 1.14%
  • 4.05

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.99%
  • 0.56%
  • 5.41%
  • FII
  • DII
  • Others
  • 7.31%
  • 10.79%
  • 0.94%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.49
  • 6.52
  • 8.96

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.69
  • 13.77
  • 10.79

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.47
  • 26.50
  • 19.20

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.31
  • 24.45
  • 23.45

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.85
  • 3.72
  • 3.79

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.20
  • 15.19
  • 14.84

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
38.14
44.97
45.35
42.82
P/E Ratio
25.29
21.45
21.27
22.53
Revenue
19022
23242
25229
26280
EBITDA
5303
6895
6841
6507
Net Income
3860
4526
4584
4329
ROA
14
13.6
11.6
10.3
P/B Ratio
6.18
4.05
3.50
3.11
ROE
20.67
20.67
17.53
14.43
FCFF
2377
5157
2398
3754
FCFF Yield
2.61
5.67
2.64
4.13
Net Debt
-553
-4595
-4244
-7547
BVPS
156.19
238.05
275.3
310.5

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
6,527.90
5,533.80
17.96%
5,269.10
4,505.20
16.96%
5,237.00
4,368.80
19.87%
6,207.50
5,139.60
20.78%
Expenses
4,402.40
3,908.60
12.63%
3,881.50
3,402.80
14.07%
3,821.00
3,304.90
15.62%
4,123.50
3,634.30
13.46%
EBITDA
2,125.50
1,625.20
30.78%
1,387.60
1,102.40
25.87%
1,416.00
1,063.90
33.10%
2,084.00
1,505.30
38.44%
EBIDTM
32.56%
29.37%
26.33%
24.47%
27.04%
24.35%
33.57%
29.29%
Other Income
80.60
161.70
-50.15%
57.50
37.70
52.52%
113.60
136.20
-16.59%
63.20
36.00
75.56%
Interest
76.60
34.60
121.39%
32.00
19.80
61.62%
25.10
8.70
188.51%
32.20
18.10
77.90%
Depreciation
237.90
205.30
15.88%
229.00
194.80
17.56%
233.60
184.20
26.82%
215.30
179.80
19.74%
PBT
1,672.00
1,547.00
8.08%
1,184.10
925.50
27.94%
1,270.90
1,007.20
26.18%
1,899.70
1,329.20
42.92%
Tax
423.20
321.20
31.76%
179.50
213.80
-16.04%
373.10
226.40
64.80%
436.10
216.10
101.80%
PAT
1,248.80
1,225.80
1.88%
1,004.60
711.70
41.15%
897.80
780.80
14.98%
1,463.60
1,113.10
31.49%
PATM
19.13%
22.15%
19.07%
15.80%
17.14%
17.87%
23.58%
21.66%
EPS
11.64
11.75
-0.94%
10.17
7.80
30.38%
9.06
7.91
14.54%
14.11
10.74
31.38%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
23,241.50
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
Net Sales Growth
18.90%
13.40%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
8.96%
 
Cost Of Goods Sold
6,338.00
5,260.10
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
Gross Profit
16,903.50
14,287.30
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
GP Margin
72.73%
73.09%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
Total Expenditure
16,228.40
14,248.40
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
Power & Fuel Cost
-
366.30
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
145.40
% Of Sales
-
1.87%
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
Employee Cost
-
2,789.00
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
% Of Sales
-
14.27%
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
Manufacturing Exp.
-
2,758.10
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
% Of Sales
-
14.11%
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
General & Admin Exp.
-
625.00
620.30
506.70
444.00
582.60
583.40
398.70
466.00
356.40
326.80
% Of Sales
-
3.20%
3.60%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
Selling & Distn. Exp.
-
1,800.10
1,674.60
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
% Of Sales
-
9.21%
9.71%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
Miscellaneous Exp.
-
649.80
595.20
548.90
548.90
525.90
371.20
404.40
502.60
416.10
1,047.20
% Of Sales
-
3.32%
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
EBITDA
7,013.10
5,299.00
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
EBITDA Margin
30.17%
27.11%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
Other Income
314.90
369.40
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
57.20
Interest
165.90
81.20
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
67.90
Depreciation
915.80
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
287.30
PBT
6,026.70
4,823.10
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
Tax
1,411.90
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
259.40
Tax Rate
23.43%
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
PAT
4,614.80
3,718.10
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
PAT before Minority Interest
4,467.70
3,831.40
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
Minority Interest
-147.10
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
PAT Margin
19.86%
19.02%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
PAT Growth
20.45%
98.80%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
64.64%
 
EPS
45.86
36.95
18.59
21.82
21.41
11.41
17.91
17.02
14.45
18.79
11.41

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
19,829.50
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
Share Capital
100.60
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
19,728.90
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
Non-Current Liabilities
193.10
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
Secured Loans
0.00
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
Unsecured Loans
0.00
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
Long Term Provisions
309.70
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
90.40
Current Liabilities
5,339.70
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
Trade Payables
2,126.70
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
Other Current Liabilities
1,677.60
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
Short Term Borrowings
768.60
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
Short Term Provisions
766.80
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
382.50
Total Liabilities
27,634.40
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
Net Block
12,368.50
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
Gross Block
19,919.80
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
Accumulated Depreciation
7,551.30
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
Non Current Assets
16,135.20
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
Capital Work in Progress
2,423.30
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
Non Current Investment
968.00
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
33.20
Long Term Loans & Adv.
344.50
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
637.10
Other Non Current Assets
30.90
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
0.00
Current Assets
11,419.80
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
Current Investments
252.50
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
121.20
Inventories
3,441.90
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
Sundry Debtors
5,220.20
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
Cash & Bank
1,105.10
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
Other Current Assets
1,400.10
274.00
229.90
523.90
1,085.50
1,080.50
1,048.40
348.50
358.90
311.50
Short Term Loans & Adv.
735.90
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
240.80
Net Current Assets
6,080.10
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
Total Assets
27,555.00
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
3,227.90
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
PBT
4,838.10
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
Adjustment
546.70
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
344.50
Changes in Working Capital
-871.10
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
Cash after chg. in Working capital
4,513.70
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,285.80
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
Cash From Investing Activity
-1,475.20
1,535.00
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
Net Fixed Assets
-572.20
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
Net Investments
-2,403.70
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
Others
1,500.70
1,965.60
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
Cash from Financing Activity
-1,810.40
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
Net Cash Inflow / Outflow
-57.70
-176.60
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
Opening Cash & Equivalents
487.80
657.80
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
Closing Cash & Equivalent
413.00
487.80
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
197.11
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
41.52
ROA
14.70%
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
ROE
20.52%
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
ROCE
24.90%
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
Fixed Asset Turnover
1.98
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
1.80
Receivable days
46.37
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
56.38
Inventory Days
32.98
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
60.13
Payable days
147.51
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
55.05
Cash Conversion Cycle
-68.16
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
61.46
Total Debt/Equity
0.04
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
0.62
Interest Cover
60.22
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75
22.29

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • USFDA concludes GMP follow-up inspection at Zydus Lifesciences’ Ahmedabad site
    19th Jun 2025, 10:08 AM

    The inspection is closed with 2 observations and none of them were related to data integrity

    Read More
  • Zydus Lifesciences gets EIR for Ankleshwar API manufacturing facility from USFDA
    12th Jun 2025, 10:12 AM

    This facility underwent an inspection from March 10, 2025 to March 14, 2025

    Read More
  • Zydus Lifesciences gets EIR for Vadodara API manufacturing facility from USFDA
    10th Jun 2025, 16:14 PM

    This facility underwent an inspection from April 21 to April 25 2025

    Read More
  • Zydus Lifesciences’ arm enters into SPA with Agenus Inc
    4th Jun 2025, 09:30 AM

    The acquisition is expected to be completed within 60 days from the date of execution of the definitive agreement, with a potential 30- days extension

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Rifaximin Tablets
    2nd Jun 2025, 09:38 AM

    The group now has 427 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences to subscribe equity shares of Torrent Urja 26, Torrent Urja 25
    29th May 2025, 11:40 AM

    The Company has entered into SSSA to acquire up to 26.20% equity shares of Torrent Urja 26, for setting up captive hybrid power project in Gujarat.

    Read More
  • Zydus Lifesciences’ NCE Usnoflast receives Fast Track Designation from USFDA
    28th May 2025, 12:50 PM

    Usnoflast is a novel oral NLRP3 inhibitor for the treatment of amyotrophic lateral sclerosis

    Read More
  • Zydus Lifesciences gets USFDA’s final nod for Isotretinoin capsules
    26th May 2025, 10:12 AM

    The group now has 427 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences receives EIR from USFDA for Ambernath facility
    14th May 2025, 15:13 PM

    The EIR report has classified it as No Action Indicated

    Read More
  • Zydus Lifesciences gets USFDA’s approval for Glatiramer Acetate Injection
    9th May 2025, 09:17 AM

    Zydus’ generic Glatiramer Acetate Injection, developed in collaboration with Chemi S.p.A., will be manufactured entirely in Europe

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Niacin Extended-Release Tablets
    30th Apr 2025, 12:23 PM

    Niacin-Extended-Release tablets will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad

    Read More
  • USFDA concludes surveillance inspection at Zydus group’s API unit in Gujarat
    28th Apr 2025, 10:08 AM

    The inspection concluded with 6 observations and none of them were related to Data Integrity

    Read More
  • Zydus Lifesciences’ arm enters into strategic partnership with Braile Biomedica Industria
    19th Apr 2025, 14:06 PM

    This agreement marks a significant step in Zydus MedTech’s strategic expansion into the fast-growing interventional cardiology segment

    Read More
  • Zydus Lifesciences’ venture capital arm invests in Feldan Therapeutics
    17th Apr 2025, 09:48 AM

    Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities

    Read More
  • Zydus Lifesciences’ US division recalls 3,144 bottles of chlorproMAZINE Hydrochloride Tablets
    14th Apr 2025, 14:16 PM

    The drug firm is recalling the affected lot due to CGMP deviations

    Read More
  • Zydus Lifesciences’ arm incorporates wholly owned subsidiary in France
    12th Apr 2025, 12:36 PM

    Zydus MedTech (France) SAS will be acquiring the equity shares of the Amplitude Surgical SA, France

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Jaythari (Deflazacort) Tablets
    12th Apr 2025, 10:39 AM

    Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy in patients 5 years of age and older

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Apalutamide Tablets
    19th Mar 2025, 09:26 AM

    Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Eluxadoline tablets
    17th Mar 2025, 10:30 AM

    Eluxadoline tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.